Access
To read this story in full you will need to login or make a payment (see right).
Letters to Editor
Nature Medicine 9, 3 - 4 (2003)
doi:10.1038/nm0103-3
Elevated 
-secretase expression and enzymatic activity detected in sporadic Alzheimer disease
Li-Bang Yang1, Kristina Lindholm1, Riqiang Yan4, Martin Citron5, Weiming Xia6, Xiao-Li Yang1, Thomas Beach2, Lucia Sue2, Philip Wong7, Donald Price7, Rena Li3 & Yong Shen1
- Haldeman Laboratory of Molecular and Cellular Neurobiology, Sun City, Arizona, USA
- Brain Bank and Civin Neuropathology Laboratory Sun City, Arizona, USA
- L.J. Roberts Center for Alzheimer's Research, Sun Health Research Institute, Sun City, Arizona, USA
- Department of Cell and Molecular Biology, Pharmacia Corp., Kalamazoo, Michigan, USA
- Department of Neuroscience, Amgen, Inc., Thousands Oaks, California, USA
- Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
- Department of Pathology, Laboratory of Neuropathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
Correspondence to: Yong Shen1 e-mail: yong.shen@sunhealth.org
A critical feature of Alzheimer disease (AD) is the deposition of plaque, which contains high levels of amyloid-
(A) peptides1. A small subset of AD patients carry the Swedish mutation2, 3 in the amyloid precursor protein (APP) gene, selectively increasing -secretase (BACE) cleavage products, of which subsequent cleavage by 
-secretase leads to A formation.
To read this story in full you will need to login or make a payment (see right).
|
MORE ARTICLES LIKE THIS These links to content published by NPG are automatically generated RESEARCH |
